Related references
Note: Only part of the references are listed.TELAPREVIR-BASED REGIMENS SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL
Ira M. Jacobson et al.
GASTROENTEROLOGY (2011)
Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or-2b to Patients With Chronic Hepatitis C
Patrick Marcellin et al.
GASTROENTEROLOGY (2011)
Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction
Alexander J. Thompson et al.
GASTROENTEROLOGY (2010)
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
Christoph Sarrazin et al.
GASTROENTEROLOGY (2010)
Hepatitis C Trials That Combine Investigational Agents with Pegylated Interferon Should Be Stratified by Interleukin-28B Genotype
Allxander J. Thomison et al.
HEPATOLOGY (2010)
Potential Role for Interleukin-28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection
Jason Grebely et al.
HEPATOLOGY (2010)
A perspective on modelling hepatitis C virus infection
J. Guedj et al.
JOURNAL OF VIRAL HEPATITIS (2010)
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
Edward J. Gane et al.
LANCET (2010)
Telaprevir for Previously Treated Chronic HCV Infection.
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Dongliang Ge et al.
NATURE (2009)
Virology of hepatitis B and C viruses and antiviral targets
JM Pawlotsky
JOURNAL OF HEPATOLOGY (2006)
Share Paper
